Methods of treating epithelioid cell tumors

1. A method of treating a malignant perivascular epithelioid tumor (PEComa) in an individual, comprising intravenously administering to the individual an effective amount of a composition comprising nanoparticles comprising sirolimus and an albumin, wherein the effective amount of sirolimus in the nanoparticle composition is about 10 mg/m 2 to about 100 mg/m 2 , and wherein the nanoparticle composition is administered on days 1 and 8 of a 21-day cycle.

2. The method of claim 1 , wherein the malignant PEComa is a pulmonary clear cell ‘sugar’ tumor or a PEComa not otherwise specified (PEComa-NOS).

3. The method of claim 1 , wherein the malignant PEComa is advanced malignant, locally advanced, metastatic, or recurrent.

4. The method of claim 1 , wherein the individual has been previously treated with an mTOR inhibitor.

5. The method of claim 1 , wherein the effective amount of sirolimus in the nanoparticle composition is less than about 50 mg/m 2 .

6. The method of claim 1 , wherein the effective amount of sirolimus in the nanoparticle composition is about 10 mg/m 2 to about 25 mg/m 2 .

7. The method of claim 1 , wherein the effective amount of sirolimus in the nanoparticle composition is about 25 mg/m 2 to about 50 mg/m 2 .

8. The method of claim 1 , wherein the effective amount of sirolimus in the nanoparticle composition is about 10 mg/m 2 to about 56 mg/m 2 .

9. The method of claim 1 , wherein the effective amount of sirolimus in the nanoparticle composition is about 45 mg/m 2 , about 30 mg/m 2 , or about 10 mg/m 2 .

10. The method of claim 1 , wherein the method is in a neoadjuvant setting.

11. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 150 nm.

12. The method of claim 1 , wherein the albumin is human albumin.

13. The method of claim 1 , wherein the albumin is human serum albumin.

14. The method of claim 1 , wherein the individual is human.